Abbott Labs opened higher at $106.15, compared with its previous close of $104.57. In the last trading session, the stock traded between $104.60 and $106.85. It showed an upward intraday trend.
An investment of $100 made 5 years ago in Abbott Labs is now worth
$ 82.67
resulting in a loss of
$ 17.33 (17.33%)
Note: Past profits do not guarantee future returns.
Rating from 17 Analysts
Today's Change
+$1.98 (+1.89%)
Day High
$106.85
Day Low
$104.60
Day Open
$106.15
Prev Close
$104.57
Volume
25,71,742
1W Return
3.93%
1M Return
5.55%
3M Return
-1.40%
6M Return
16.67%
1Y Return
-14.37%
Market Cap ($ Mn)
1,84,374
PE Ratio
36.28
PB Ratio
3.81
PEG Ratio
15.55
ROE
13.04%
ROCE
12.50%
EPS (TTM)
$0.54
1 Week
3.93%
1 Month
5.55%
3 Months
-1.40%
6 Months
16.67%
9 Months
0.43%
Abbott plans nutrition spinoff as Q3 revenue rises 14.5%
Abbott plans to spin off its $8.5 billion nutrition business by end-2027. Q3 revenue rose 14.5% YoY to $13.013 billion, beating estimates. Full-year comparable sales growth forecast lowered to ~6% from 6.5%-7.5%. Diabetes growth outlook revised to high-single-digit for FY26.
8 days agoAbbott Laboratories Q3FY26 Results: Revenue beats estimates at $13.013 billion
Revenue reached $13.013 billion, beating consensus estimate by 0.12%. Adjusted EPS of $1.42 met analyst expectations. Sales grew 14.46% YoY from $11.369 billion in Q3FY25. EPS increased 9.23% YoY from $1.30.
9 days agoAbbott Labs upgraded to Buy with $127 target among top analyst moves
Rothschild & Co upgraded Abbott Laboratories to Buy, raising the price target to $127. Argus Research increased Accenture's price target to $260 while maintaining a Buy rating. Baird cut Nike's price target to $36 from $44, maintaining a Neutral rating. HC Wainwright lowered Foghorn Therapeutics' target to $5 from $13, keeping a Buy rating.
28 days agoFDA approves Abbott's first wearable dual glucose ketone monitor
FDA approves Abbott's Libre Duo 10 Day as first U.S. wearable for continuous dual glucose and ketone tracking. Device targets patients aged two and older, offering up to 10 days of wear time. Integration with Beta Bionics and Sequel Med Tech pumps expected by end of this year. William Blair highlights potential competitiveness in pediatric market post-integration.
2mo agoAbbott settles infant formula litigation for $670 million
Abbott settles Gill lawsuit and 2,000 NEC claims for $670 million. Company bypassed appeals after Missouri court denied December 2024 request. Roughly 1,700 lawsuits involving 12,700 infants remain pending. FDA and CDC maintain no scientific link between formulas and NEC.
2mo agoRep. McCormick sold up to $375,000 of Abbott Labs stock
Georgia Representative Richard Dean Dr McCormick disposed of Abbott Laboratories (NYSE: ABT) stock worth between $25,025 and $375,000. The July 30, 2026 transaction was filed in August 2026. Abbott shares declined 0.63% to $110.19 during the reporting period.
2mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $448.76 | +1.03% | $1,55,559.96M | 42.73 | |
| $97.11 | +2.46% | $1,24,220.20M | 24.46 | |
| $311.75 | +2.55% | $1,19,578.88M | 34.27 | |
| $42.69 | +0.61% | $61,867.63M | 18.96 | |
| $94.44 | +2.90% | $54,435.22M | 53.70 | |
| $198.34 | +1.63% | $54,025.24M | 44.07 | |
| $252.83 | +1.06% | $35,557.76M | 23.04 | |
| $76.42 | +0.79% | $34,552.39M | 16.49 | |
| $71.13 | +1.86% | $34,384.24M | 54.55 | |
| $79.93 | +1.67% | $30,162.46M | 36.04 | |
| $416.67 | +3.23% | $29,323.57M | 43.21 | |
| $32.00 | -1.14% | $28,075.23M | 89.05 |
An investment of $100 made 5 years ago in Abbott Labs is now worth
$ 82.67
resulting in a loss of
$ 17.33 (17.33%)
Note: Past profits do not guarantee future returns.
